Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Nina Trokovic"'
Autor:
Johan Askling, Eirik Klami Kristianslund, Elizabeth V Arkema, Lene Dreyer, Bjorn Gudbjornsson, Gerður Gröndal, Kalle Aaltonen, Bénédicte Delcoigne, Tine Iskov Kopp, Nina Trokovic, Sella Aarrestad Provan, Heikki Relas, Jesper Lindhardsen, Karin Hellgren
Publikováno v:
RMD Open, Vol 9, Iss 1 (2023)
Objective To compare incidences of neuroinflammatory events, including demyelinating disease (DML), inflammatory polyneuropathies (IPN) and multiple sclerosis (MS), in patients with rheumatoid arthritis (RA) or spondyloarthritis (SpA; including psori
Externí odkaz:
https://doaj.org/article/67010e8191194d128e4fe7d7b7fe085e
Autor:
Bente Glintborg, Johan Askling, Katerina Chatzidionysiou, Lene Dreyer, Thomas Frisell, Kalle Aaltonen, Bénédicte Delcoigne, Merete L Hetland, René Cordtz, Kristian Zobbe, Nina Trokovic, Sella Aarrestad Provan
Publikováno v:
RMD Open, Vol 6, Iss 2 (2020)
Externí odkaz:
https://doaj.org/article/026b4bc48a814017938158ca6276aaaf
Autor:
Anna-Mari Hokkanen, Kalle Aaltonen, Heikki Relas, Jarno Rutanen, Aulikki Kononoff, Kirsi Taimen, Markku Kauppi, Kari Puolakka, Nina Trokovic, Dan Nordström
Publikováno v:
Rheumatology Advances in Practice.
Objectives To investigate the effect of tumor necrosis factor inhibitor (TNFi) initiation on working ability and health care resource utilization among axial spondyloarthritis patients in a real-life setting. Methods Patients with a clinical diagnosi
Autor:
Benedicte Delcoigne, Tine Iskov Kopp, Elizabeth V Arkema, Karin Hellgren, Sella Aarrestad Provan, Heikki Relas, Kalle Aaltonen, Nina Trokovic, Bjorn Gudbjornsson, Gerdur Grondal, Eirik Klami Kristianslund, Jesper Lindhardsen, Lene Dreyer, Johan Askling
Publikováno v:
Delcoigne, B, Kopp, T I, Arkema, E V, Hellgren, K, Provan, S A, Relas, H, Aaltonen, K, Trokovic, N, Gudbjornsson, B, Grondal, G, Klami Kristianslund, E, Lindhardsen, J, Dreyer, L & Askling, J 2023, ' Exposure to specific tumour necrosis factor inhibitors and risk of demyelinating and inflammatory neuropathy in cohorts of patients with inflammatory arthritis : a collaborative observational study across five Nordic rheumatology registers ', RMD Open, vol. 9, no. 1, e002924 . https://doi.org/10.1136/rmdopen-2022-002924
Objective: To compare incidences of neuroinflammatory events, including demyelinating disease (DML), inflammatory polyneuropathies (IPN) and multiple sclerosis (MS), in patients with rheumatoid arthritis (RA) or spondyloarthritis (SpA; including psor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d90bad207c85072b502d111bd5f390d7
https://vbn.aau.dk/da/publications/f8f18d76-a835-4998-ad54-5d58d92af0fc
https://vbn.aau.dk/da/publications/f8f18d76-a835-4998-ad54-5d58d92af0fc
Autor:
Dan Nordström, Tore K Kvien, Lene Dreyer, Nina Trokovic, Karin Hellgren, Katerina Chatzidionysiou, Tanja Schjødt Jørgensen, Gerdur Grondal, Daniela Di Giuseppe, Sella Aarrestad Provan, Thomas Frisell, Lennart T H Jacobsson, Bjorn Gudbjornsson, Johan Askling, Lars Erik Kristensen, Eirik Kristianslund, Kalle Aaltonen, Merete Lund Hetland, Ritva Peltomaa, Bente Glintborg
Publikováno v:
Chatzidionysiou, K, Hetland, M L, Frisell, T, Di Giuseppe, D, Hellgren, K, Glintborg, B, Nordström, D, Peltomaa, R, Aaltonen, K, Trokovic, N, Kristianslund, E K, Kvien, T K, Provan, S A, Gudbjornsson, B, Grondal, G, Dreyer, L, Kristensen, L E, Jørgensen, T S, Jacobsson, L T H & Askling, J 2021, ' Effectiveness of a second biologic after failure of a non-tumor necrosis factor inhibitor as first biologic in rheumatoid arthritis ', Journal of Rheumatology, vol. 48, no. 10, jrheum.201467, pp. 1512-1518 . https://doi.org/10.3899/jrheum.201467
ObjectiveIn rheumatoid arthritis (RA), evidence regarding the effectiveness of a second biologic disease-modifying antirheumatic drug (bDMARD) in patients whose first-ever bDMARD was a non–tumor necrosis factor inhibitor (TNFi) bDMARD is limited. T
Autor:
Irene E. van der Horst-Bruinsma, Manuel Pombo-Suarez, Tore K Kvien, Helena Santos, Johan K. Wallman, Sema Yilmaz, Ruxandra Ionescu, Lucie Nekvindová, Nina Trokovic, Kari K. Eklund, Maria José Santos, Ennio Giulio Favalli, Bjorn Gudbjornsson, Stylianos Georgiadis, Gareth T. Jones, Yavuz Pehlivan, Merete Lund Hetland, Florenzo Iannone, Carlos Sánchez-Piedra, Catalin Codreanu, Eirik Kristianslund, Anne Gitte Loft, Daniela Di Giuseppe, Ziga Rotar, Matija Tomšič, Brigitte Michelsen, Mikkel Østergaard, Burkhard Möller, Lykke Midtbøll Ørnbjerg, Michael John Nissen, Cecilie Heegaard Brahe, Herman Mann, Thorvardur Jon Love
Publikováno v:
Michelsen, B, Georgiadis, S, Di Giuseppe, D, Loft, A G, Nissen, M J, Iannone, F, Pombo-Suarez, M, Mann, H, Rotar, Z, Eklund, K K, Kvien, T K, Santos, M J, Gudbjornsson, B, Codreanu, C, Yilmaz, S, Wallman, J K, Brahe, C H, Möller, B, Favalli, E G, Sánchez-Piedra, C, Nekvindova, L, Tomsic, M, Trokovic, N, Kristianslund, E K, Santos, H, Löve, T J, Ionescu, R, Pehlivan, Y, Jones, G T, van der Horst-Bruinsma, I, Ørnbjerg, L M, Østergaard, M & Hetland, M L 2022, ' Real-World Six-and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries ', Arthritis Care and Research, vol. 74, no. 7, pp. 1205-1218 . https://doi.org/10.1002/acr.24560
Arthritis Care & Research, 74, 7, pp. 1205-1218
Arthritis Care & Research, 74, 1205-1218
Arthritis Care & Research, 74, 7, pp. 1205-1218
Arthritis Care & Research, 74, 1205-1218
Contains fulltext : 251829.pdf (Publisher’s version ) (Open Access) OBJECTIVE: There is a lack of real-life studies on interleukin-17 (IL-17) inhibition in psoriatic arthritis (PsA). We assessed real-life 6- and 12-month effectiveness (i.e., retent
Autor:
Sella Aarrestad Provan, Lotta Ljung, Johan Askling, N. Steen Krogh, K. Lederballe Gron, Brigitte Michelsen, Nina Trokovic, Heikki Relas, B. Glintborg, M.L. Hetland, Carl Turesson, Bénédicte Delcoigne
Publikováno v:
Annals of the Rheumatic Diseases. 80:63-64
Background:Rheumatoid Arthritis (RA) is associated with increased cardiovascular co-morbidity including acute coronary syndrome (ACS), partly due to effects of systemic inflammation. Disease-modifying anti-rheumatic drugs (DMARDs) may reduce RA disea
Autor:
Katerina Chatzidionysiou, Gerdur Grondal, Dan Nordström, Johan Askling, Bjorn Gudbjornsson, Kristian Zobbe, Lene Dreyer, Merete Lund Hetland, René Cordtz, Bénédicte Delcoigne, Bente Glintborg, Nina Trokovic, Kalle Aaltonen, Sella Aarrestad Provan, Thomas Frisell
Publikováno v:
Chatzidionysiou, K, Delcoigne, B, Frisell, T, Hetland, M L, Glintborg, B, Dreyer, L, Cordtz, R, Zobbe, K, Nordström, D, Trokovic, N, Aaltonen, K, Provan, S A, Grondal, G, Gudbjornsson, B & Askling, J 2020, ' How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers ', RMD Open, vol. 6, no. 2, e001363 . https://doi.org/10.1136/rmdopen-2020-001363
RMD Open
Chatzidionysiou, K, Delcoigne, B, Frisell, T, Hetland, M L, Glintborg, B, Dreyer, L, Cordtz, R, Zobbe, K, Nordström, D, Trokovic, N, Aaltonen, K, Provan, S A, Grondal, G, Gudbjornsson, B & Askling, J 2020, ' How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers ', RMD Open, vol. 6, no. 2, 001363 . https://doi.org/10.1136/rmdopen-2020-001363
RMD Open, Vol 6, Iss 2 (2020)
RMD Open
Chatzidionysiou, K, Delcoigne, B, Frisell, T, Hetland, M L, Glintborg, B, Dreyer, L, Cordtz, R, Zobbe, K, Nordström, D, Trokovic, N, Aaltonen, K, Provan, S A, Grondal, G, Gudbjornsson, B & Askling, J 2020, ' How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers ', RMD Open, vol. 6, no. 2, 001363 . https://doi.org/10.1136/rmdopen-2020-001363
RMD Open, Vol 6, Iss 2 (2020)
Publisher's version (útgefin grein)
[No abstract available]
This study was partly funded by grants from Nord-Forsk and FOREUM.
[No abstract available]
This study was partly funded by grants from Nord-Forsk and FOREUM.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f36de21727010970f3b2dae0cff1e91
https://vbn.aau.dk/ws/files/350946479/Chatzidionysiou_et_al._2020_How_do_we_use_biologics_in_rheumatoid_arthritis_patients_with_a_history_of_malignancy
https://vbn.aau.dk/ws/files/350946479/Chatzidionysiou_et_al._2020_How_do_we_use_biologics_in_rheumatoid_arthritis_patients_with_a_history_of_malignancy
Autor:
Johan Askling, Kathrine Lederballe Grøn, Lennart T H Jacobsson, Dan Nordström, Sella Aarrestad Provan, Brigitte Michelsen, Lars Erik Kristensen, Tanja Schjødt Jørgensen, Bente Glintborg, Ulf Lindström, Bjorn Gudbjornsson, Merete Lund Hetland, Johan K. Wallman, Thorvardur Jon Love, Nina Trokovic, Niels Steen Krogh, Daniela Di Giuseppe
Publikováno v:
Rheumatology (Oxford, England). 60(8)
Objectives To compare treatment retention and response to secukinumab vs adalimumab, including the other four TNF inhibitors (TNFi) as comparators, in PsA. Methods All patients with PsA starting secukinumab or a TNFi in 2015–2018 were identified in
Autor:
Maria José Santos, Kari K. Eklund, Catalin Codreanu, Johan Askling, Nina Trokovic, Gary J. Macfarlane, Ennio Giulio Favalli, Irene E. van der Horst-Bruinsma, Bjorn Gudbjornsson, Servet Akar, Anne Gitte Loft, Heřman Mann, Mikkel Ǿstergaard, Merete Lund Hetland, Manuel Pombo-Suarez, Florenzo Iannone, Eirik Kristianslund, Fatos Onen, Lise Hyldstrup, Arni Jon Geirsson, Michael John Nissen, Karel Pavelka, Brigitte Michelsen, Carlos Sánchez-Piedra, Cecilie Heegaard Brahe, Helena Santos, Ziga Rotar, Daniela Di Giuseppe, Niels Steen Krogh, Matija Tomšič, Adrian Ciurea, Joseph O. Sexton, Ruxandra Ionescu
Publikováno v:
Spondyloarthritis – treatment.
Background There is a lack of real-life data on secukinumab exposure, treatment outcomes and retention rates in axial spondyloarthritis (axSpA) patients. Objectives Primary objective: To assess the proportion of axSpA patients in BASDAI low disease a